Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, Netherlands.
Department of Experimental and Applied Medicine, Cardiology Unit, University of Brescia, Brescia, Italy.
Eur J Cardiothorac Surg. 2018 Jul 1;54(1):10-18. doi: 10.1093/ejcts/ezy019.
Candidate patients for cardiac surgery procedures with a history of malignancies and antitumour therapy or with an active cancer and on antineoplastic treatment are increasingly common in daily practice. Oncological therapy can lead to cardiovascular injury and, therefore, has the potential for impacting operative risks and surgical strategies. This means that a number of considerations are essential to take into account prior to cardiac surgery. These include the type of cancer, previous cardiotoxicity or concomitant antitumour therapy, reversibility or irreversibility of such complications, the interaction between cancer disease course and extracorporeal circulation, the need for associated surgery and the impact of cancer on early and long-term outcomes. Adequate preoperative evaluation of cardiovascular abnormalities potentially related to antineoplastic therapy and proper diagnostic workup of other conditions linked to the type of cancer (e.g. haematological disorders and lung dysfunction) are therefore of paramount importance for appropriate surgical decision-making. Careful evaluation of the association of cardiovascular disease to be treated and the prognosis of remitted or active cancer should be established to enhance the prediction of early, medium and long-term outcomes and for a more correctly informed patient. Furthermore, if the prognosis of operated patients appears unfavourable, then alternative therapeutic strategies can be applied without significant delay. The aim of this review is to give an overview of factors that should be considered in adult patients who are undergoing, or have undergone, treatment for oncological indications who are candidates for cardiac surgery.
患有恶性肿瘤和抗肿瘤治疗史或患有活动性癌症且正在接受抗肿瘤治疗的心脏手术患者在日常实践中越来越常见。肿瘤治疗可导致心血管损伤,因此有可能影响手术风险和手术策略。这意味着在进行心脏手术之前,需要考虑许多因素。这些因素包括癌症类型、先前的心脏毒性或同时进行的抗肿瘤治疗、这些并发症的可逆性或不可逆性、癌症病程与体外循环之间的相互作用、相关手术的必要性以及癌症对早期和长期结果的影响。因此,充分评估与抗肿瘤治疗相关的心血管异常,并对与癌症类型相关的其他疾病(例如血液系统疾病和肺功能障碍)进行适当的诊断检查,对于做出适当的手术决策至关重要。需要仔细评估待治疗的心血管疾病与已缓解或活动性癌症的预后,以提高对早期、中期和长期结果的预测,并为患者提供更准确的信息。此外,如果手术患者的预后似乎不佳,则可以毫不拖延地应用替代治疗策略。本综述的目的是概述接受或已接受肿瘤治疗适应证且适合心脏手术的成年患者应考虑的因素。